Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism

Current Medical Research and Opinion

Volumn 30, Issue 5, 2014, Pages 829-837

  Van Bellen, Bonno ^a   Bamber, Luke ^b   Correa De Carvalho, Francine ^c   Prins, Martin ^d   Wang, Maria ^e   Lensing, Anthonie W A ^b  

^a HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^b BAYER PHARMA AG   (Germany)

^c Bayer HealthCare   (Brazil)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e BAYER CORPORATION   (United States)

Author keywords

Deep vein thrombosis; Hospitalization; Length of stay; Pulmonary embolism; Rivaroxaban

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; ENOXAPARIN; RIVAROXABAN; WARFARIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; ENOXAPARIN; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MORPHOLINES; PULMONARY EMBOLISM; THIOPHENES; VENOUS THROMBOSIS; VITAMIN K;

EID: 84899108797     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.879439     Document Type: Article

References (34)

1. Wong P, Baglin T. Epidemiology, risk factors and sequelae of venous thromboembolism. Phlebology 2012;27(Suppl 2):2-11
2. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419-94S
3. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011;62:41-57
4. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010;121:1523-32
5. Knight KK, Wong J, Hauch O, et al. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health 2005;8:191-200
6. Rymes NL, Lester W, Connor C, et al. Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clin Lab Haematol 2002;24:165-70
7. Labas P, Ohradka B, Vladimir J, et al. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression. Int Angiol 2000;19:303-7
8. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81
9. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-7
10. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62
11. Panis LJ, Kolbach DN, Hamulyak K, et al. Identifying inappropriate hospital stay in patients with venous thromboembolism. Eur J Intern Med 2004;15:39-44
12. Stein PD, Hull RD, Matta F, et al. Early discharge of patients with venous thromboembolism: Implications regarding therapy. Clin Appl Thromb Hemost 2010;16:141-5
13. Spyropoulos A, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: An administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
14. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
15. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
16. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism; NICE technology appraisal guidance 261. National Institute for Health and Clinical Excellence, 2012. Available at: Http://www.nice.org.uk/nicemedia/live/13805/60040/60040.pdf [Last accessed 10 December 2013]
17. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism TA287. National Institute for Health and Care Excellence, 2013. Available at: Http://guidance.nice.org.uk/TA287/Guidance/pdf/English [Last accessed 11 September 2013]
18. Prins MH, Lensing AWA, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21
19. Prins MH, Lensing AWA. Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J 2013;11:13
20. Venous thromboembolic diseases: The management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guidelines, CG144. National Institute for Health and Care Excellence, 2012. Available at: Http://guidance.nice.org.uk/CG144 [Last accessed 10 December 2013]
21. Cohen A, Chiu KM, Park K, et al. Managing venous thromboembolism in Asia: Winds of change in the era of new oral anticoagulants. Thromb Res 2012;130:291-301
22. Aujesky D, Stone RA, Kim S, et al. Length of hospital stay and postdischarge mortality in patients with pulmonary embolism: A statewide perspective. Arch Intern Med 2008;168:706-12
23. van Bladel ER, Agterof MJ, Frijling BD, et al. Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect. Thromb Res 2010;126:481-5
24. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315
25. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: Increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000;83:416-20
26. Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: Validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003;163:917-20
27. Erkens PM, Gandara E, Wells PS, et al. Does the Pulmonary Embolism Severity Index accurately identify low risk patients eligible for outpatient treatment? Thromb Res 2012;129:710-14
28. Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: The Hestia Study. J Thromb Haemost 2011;9:1500-7
29. Squizzato A, Galli M, Dentali F, et al. Outpatient treatment and early discharge of symptomatic pulmonary embolism: A systematic review. Eur Respir J 2009;33:1148-55
30. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: An international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41-8
31. Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A US perspective. Thromb Res 2013;132:647-51
32. Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014;17:52-64
33. Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013;110:732-41
34. Prins M, Bamber L, Cano S, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood (ASH Annual Meeting Abstracts) 2012;120:Abstract 1163.